Volasertib - Boehringer Ingelheim/Oncoheroes Biosciences
Alternative Names: BI-6727Latest Information Update: 26 Jul 2024
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Oncoheroes Biosciences
- Class Amides; Antineoplastics; Piperazines; Pteridines; Small molecules
- Mechanism of Action Polo-like kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia
- Phase II Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer
- No development reported Chronic myelomonocytic leukaemia; Rhabdomyosarcoma; Solid tumours; Urogenital cancer
Most Recent Events
- 24 Jul 2024 US FDA approves IND application for Volasertib in Acute myeloid leukemia (Second-line therapy or greater)
- 03 Jun 2024 Notable Labs has patent protection for volasertib in USA, European Patent Office, Germany, France, United Kingdom, and Japan before June 2024
- 05 Apr 2024 Parmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)